Fresenius Medical Care AG (ETR:FME - Get Free Report)'s share price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of €45.90 ($52.76) and traded as high as €49.72 ($57.15). Fresenius Medical Care shares last traded at €47.28 ($54.34), with a volume of 1,054,992 shares.
Fresenius Medical Care Price Performance
The firm has a market capitalization of $13.75 billion, a P/E ratio of 20.86, a P/E/G ratio of 0.42 and a beta of 0.86. The company has a debt-to-equity ratio of 82.24, a current ratio of 1.37 and a quick ratio of 0.80. The stock's fifty day simple moving average is €47.94 and its 200 day simple moving average is €45.96.
Fresenius Medical Care Company Profile
(
Get Free Report)
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Further Reading
Before you consider Fresenius Medical Care, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius Medical Care wasn't on the list.
While Fresenius Medical Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.